skip to main content

H.R. 3379: Price Relief, Innovation, and Competition for Essential Drugs Act

Call or Write Congress

To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.

The bill’s titles are written by its sponsor.

Sponsor and status

Janice “Jan” Schakowsky

Sponsor. Representative for Illinois's 9th congressional district. Democrat.

Read Text »
Last Updated: Jun 20, 2019
Length: 2 pages
Introduced
Jun 20, 2019
Status

Introduced on Jun 20, 2019

This bill is in the first stage of the legislative process. It was introduced into Congress on June 20, 2019. It will typically be considered by committee next before it is possibly sent on to the House or Senate as a whole.

Prognosis
23% chance of being enacted according to Skopos Labs (details)
Source

Position statements

What legislators are saying

Bill Introduced to Reduce Prescription Drug Companies Exclusivity Period
    — Rep. Janice “Jan” Schakowsky [D-IL9] (Sponsor) on Jun 21, 2019

Congressman Krishnamoorthi and Colleagues Introduce Bipartisan Legislation To Reduce Prescription Drug Prices
    — Rep. Raja Krishnamoorthi [D-IL8] (Co-sponsor) on Jun 21, 2019

ICYMI: Why Is This Lone GOP Rep Supporting A Democratic Drug Price Bill?
    — Rep. Bruce Westerman [R-AR4] (Co-sponsor) on Jun 25, 2019

More statements at ProPublica Represent...

History

Jun 20, 2019
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

If this bill has further action, the following steps may occur next:
 
Passed Committee

 
Passed House

 
Passed Senate

 
Signed by the President

H.R. 3379 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 3379 — 116th Congress: Price Relief, Innovation, and Competition for Essential Drugs Act.” www.GovTrack.us. 2019. July 18, 2019 <https://www.govtrack.us/congress/bills/116/hr3379>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.